AHPC 5-in-1 COVID-19, RSV, Influenza A/B & Adenovirus Rapid Antigen Test

AHPC 5-in-1 COVID-19, RSV, Influenza A/B & Adenovirus Rapid Antigen Test

Brand: Australia Health Products Central
SKU: AHPC-8000138
11.33 AUD In stock Buy at Merchant

Test for Five Common Respiratory Viruses The AHPC 5-in-1 Antigen Combo Rapid Test Kit is a self-test designed for the rapid qualitative detection of five respiratory viruses using a single anterior nasal swab. The test detects antigens associated with: SARS-CoV-2, the virus that causes COVID-19 Influenza A Influenza B Respiratory Syncytial Virus (RSV) Adenovirus (ADV) Convenient At-Home Testing Using lateral flow immunoassay technology, the test provides rapid qualitative results and can assist in identifying which of these common respiratory viruses may be present. The test is intended for self-testing using an anterior nasal swab. Always read the complete Instructions for Use before performing the test. Your browser does not support the video player. Instructions for Use Follow all preparation, sample collection, testing and result-interpretation instructions provided by the manufacturer. Download the Instructions for Use Important Information This test is intended to assist with the detection of SARS-CoV-2, Influenza A, Influenza B, RSV and Adenovirus antigens. Test results should not be used as the sole basis for diagnosing or excluding an infection. A negative result does not completely rule out infection. Consider your symptoms, follow the Instructions for Use carefully and seek medical advice when appropriate. ARTG inclusion number: 524286 Reporting Performance or Usability Issues To report a medical device incident, call 1800 809 361 or email iris@health.gov.au.

Specifications
Pack Size
Box of 2, Box of 6, Box of 10
Variants (3)
  • Box of 2 — 11.33 AUD — In stock
  • Box of 6 — 32.54 AUD — In stock
  • Box of 10 — 49.50 AUD — In stock

How AI sees this product

The more complete this product's details, the more confidently AI assistants can understand and recommend it.

87%